Background: Doubts have been raised concerning the therapeutic efficacy of sulfadoxine-pyrimethamine due to
INTRODUCTION
A study raised doubts about the therapeutic efficacy of sulfadoxine-pyrimethamine due to poor clinical response, necessitating the need for continuous monitoring and further advocated the replacement of sulfadoxine-pyrimethamine with suitable alternatives (1) .
Indeed, the therapeutic life of sulfadoxine-pyrimethamine was predicted to last for only five years following its introduction in Africa as alternative to chloroquine, due to high transmission rates of malaria. Sulfadoxine-pyrimethamine has been recommended by World Health Organisation (WHO), for intermittent preventive therapy (IPT) in pregnancy, particularly in the disease endemic zones (2) . A study hypothesized that combination of molecular and epidemiological factors may be implicated in the clinical efficacy of sulfadoxine-pyrimethamine (3) . The declining clinical efficacy and parasite clearance rates, all point to the dire need for novel effective treatment of malaria infection. A number of mechanisms acting through various organ systems are involved in the pathophysiology of malaria infection (4) . Statins are known to down regulate biosynthesis of dolichol and isoprenoid pyrophosphate, inhibiting in vitro growth of Plasmodium falciparum (5) . A study revealed that the clinical benefit of statins could be attributed not onl;y to improvement in endothelial function, but a significant reduction in anti-inflammatory effects (6) . Simvastatin has been shown to reduce tumor necrosis factor-α (TNF-α), Interleukin-1(IL-1) and proinflammatory cytokines (7, 8) . The production of TNF-α and IL-1 is induced by glycosylphosphatidylinositol (GPI) produced by Plasmodium falciparum, leading to TNF-α induced weight loss in malaria infection (9, 10) . Consequently, the present study was aimed at evaluating the clinical response of simvastatin plus sulfadoxine-pyrimethamine (test group) combination as compared to sulfadoxine-pyrimethamine alone (control group) in the chemotherapy of malaria.
METHODS

Subjects:
The subjects selected for this stuidy were patients in attendance at primary health facilities (n=60) suffering from malaria infection, diagnosed using thick blood films and Subjects were randomised into test and control groups using a table of random numbers statistically generated. The principal investigator, microscopist, field supervisor, field assistants, medical officer, nurses and all other participants in the study did not have any prior knowledge of the patients' medical records nor the treatment group to which each subject was o Recrudescence Rate (RR): The proportion of subjects in which there is incomplete clearance of parasitemia on D14 and D28 of follow-up.
Statistical Analysis: The analysis of data was facilitated using Graphpad Prism version 4.0 (GraphPad Software, Inc., La Jolla, CA, USA) statistical software and data presented in tabular and graphical forms. Statistical test of significance ascertained using two-tailed Student t-test, assuming p<0.05 considered significant at 95% confidence interval. Table 1 depicts the baseline characteristics of test and control groups at presentation. Table 2 shows mean values of treatment failure in patients treated with sulfadoxinepyrimethamine and simvastatin (test) and those treated with sulfadoxine-pyrimethamine alone (control). Table 3 It has already been documented that sulfadoxine-pyrimethamine may or may not enhance gametocyte carriage during treatment of acute falciparum infections 13, 14) . Notwithstanding, that the presence of gametocytes in peripheral blood after anti-malarial treatment was no proof of viability, their generation was required for the transmission of the infection from the vertebrates to the anopheline host. Instructively, it was not clear whether the enhancement or non-enhancement of gametocyte production by sulfadoxine-pyrimethamine will be influenced by its use in combination with statins. However, it has been shown that peripheral young gametocytes (PYG) were not an indicator of response to sulfadoxine-pyrimethamine, since both sulfadoxine-pyrimethamine sensitive and resistant infections generated peripheral young gametocytes. Thus, the non-determination of gametocyte carriage status may not necessarily be considered a limitation in the present study.
RESULTS
This study reported a relatively higher therapeutic failure in the control compared to test group treated with sulfadoxine-pyrimethamine as shown in The total treatment failure of 19.5% in the test group treated with sulfadoxine-pyrimethamine was considered below the 25% limit recommended for centers in the high endemicity of malaria transmission. The early treatment failure (ETF) rate of 9.2% reported in the test group was still below the 10% margin recommended for change in first line anti-malarial therapy as compared to 20.5% in the control. Consequently, the continuous use of sulfadoxine-pyrimethamine will create an apparent well-being but engender a tendency to chronic malaria morbidity in the study population particularly the control.
The World Health Organization has consistently recommended to malaria control programs in Africa to rely more on clinical rather than parasitological response in assessment of anti-malarial efficacy. The widespread decline in chloroquine efficacy three decades ago, then necessitated many African countries to adopt sulfadoxine-pyrimethamine as first line therapy in treatment of uncomplicated falciparum malaria. However, progressive decline in sensitivity of Plasmodium falciparum to sulfadoxine-pyrimethamine had since been reported (16, 17) .
The mean fever clearance time (FCT) in this study is as given in Table 3 . This was as compared to 33.6 hours reported in an earlier study (18) . However, recent studies in SouthWest and South-East Nigeria revealed fever clearance time of 52.8 and 74.6 hours respectively in subjects treated with sulfadoxine-pyrimethamine alone, which corroborated results in the present study (12, 19) . The fever clearance time of 33.6 hours and parasite clearance time of 3.9 days obtained in a previous study differed significantly from the values obtained in control group treated with sulfadoxine-pyrimethamine in the present study. This was not surprising as the previous study was carried out over a decade ago when clinical response to sulfadoxine-pyrimethamine was far more reliable.
The mean parasite clearance time (PCT) reported for this study is as shown in Table   3 . This was as compared to a recent study which reported parasite clearance time of 6.1days
in subjects treated with sulfadoxine-pyrimethamine alone (19) . The time to 50% and 90%
clearance (PC 50 and PC 90 ) for the said study were given as 0.82 and 1.12 days respectively. It further highlighted that indices of therapeutic response estimated by conventional methods, that is time to 50% or 90% reduction of parasitemia and parasite clearance time, were sufficiently higher than those derived from the corresponding functional viability estimate ex vivo for sulfadoxine-pyrimethamine. However, the conventional method employed in the present study was unable to differentiate viable from non-viable circulating parasites (20) .
The recrudescence rates reported in this study were 19.1% and 39% in the test and control groups respectively treated with sulfadoxine-pyrimethamine. However, clinical clearance rate of 82.3% and 60% were reported in the present study for the test and control groups respectively. The above values correlated with cure rate of 74.5% and 55.9% reported for the test and control groups respectively in this study.
The trophozoite stage of malaria parasite which is analogous to G 1 phase of the mammalian cell cycle, is susceptible to simvastatin; and the cytostatic effects observed related to G Above depicted linear graphical representation of the progressive decline in the level of parasitemia in both test and control subjects treated with sulfadoxine-pyrimethamine. It revealed mean geometric parasite density of 9635/μL, 2971/μL, 1076/μL, 217/μL and 13/μL for days 0, 3, 7, 14 and 28 respectively in the test subjects. This was as compared to the mean geometric parasite density of 8791/μL, 4098/μL, 1934/μL, 650/μL and 326/μL for days 0, 3, 7, 14 and 28 respectively in the control subjects.
